Tao H, Shi L, Zhou A, et al. - In patients with surgically resected non-small cell lung cancer (NSCLC), researchers investigated the distribution of anaplastic lymphoma kinase fusion (ALK) variants as well as prognostic factors. This study involved 55 early stage patients with histological adenocarcinoma. The main variant type was echinoderm microtubule-associated protein-like 4- anaplastic lymphoma kinase ( EML4-ALK) variant 1, followed by EML4-ALK variant 3 and variant 2. TP53 mutations were identified to be the most commonly seen among coexisting mutations, though they were seen less frequently in the variant 1 group. Overall, in patients having resected NSCLC, worse prognosis was observed in relation to advanced T stage and EML4-ALK variant 3. The role of TP53 mutations in prognosis merits further inquiry.